The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Projected Increase In Market Value Of The Stelara (Ustekinumab) Market During 2026–2030?
The stelara (ustekinumab) market size has demonstrated robust growth in recent years. It is projected to increase from $11.85 million in 2025 to $12.54 million in 2026, at a compound annual growth rate (CAGR) of 5.9%. The expansion observed historically stems from several factors, including the limitations of conventional immunosuppressants, the rising prevalence of autoimmune diseases, compelling clinical efficacy data, the practice of hospital-based biologic administration, and the ongoing demand for durable remission.
The market for stelara (ustekinumab) is projected to experience substantial expansion in the coming years. By 2030, its valuation is anticipated to reach $15.57 million, demonstrating a compound annual growth rate (CAGR) of 5.5%. This projected growth during the forecast period is driven by several factors, including an increase in inflammatory bowel disease incidents, broader biologic reimbursement access, patient demand for less frequent administration, the influence of biosimilar competition, and advancements in biologic delivery systems. Key trends foreseen over this period encompass a heightened utilization of targeted biologic treatments, an broadening of indications for autoimmune diseases, a move towards sustained maintenance therapies, increasing acceptance of subcutaneous biologics, and a rise in self-administered treatments at home.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19935&type=smp
Which Strong Drivers Are Impacting The Stelara (Ustekinumab) Market Growth?
An increasing number of individuals diagnosed with psoriasis is projected to drive the expansion of the stelara (ustekinumab) market moving forward. Psoriasis is a persistent autoimmune condition where skin cell regeneration is accelerated, leading to characteristic red, flaky skin patches. This rise in prevalence can be attributed to various factors, including advancements in diagnosis, environmental triggers, genetic susceptibility, and an aging demographic. Stelara (ustekinumab) works by targeting and blocking interleukin-12 and interleukin-23, thereby assisting psoriasis sufferers through effective reduction of inflammation and plaque development, which results in clearer skin and sustained symptom control, ultimately improving their overall quality of life. For instance, according to an August 2024 report by the National Psoriasis Foundation (NPF), a US-based non-profit organization, psoriasis impacts approximately 3% of U.S. adults aged 20 and over, totaling more than 7. million individuals. Additionally, an estimated 600,000 adults in the country are believed to have psoriasis but remain undiagnosed. Consequently, the growing prevalence of psoriasis patients is anticipated to fuel the expansion of the stelara (ustekinumab) market.
Which Segment Categories Are Included In The Stelara (Ustekinumab) Market Segment Analysis?
The stelara (ustekinumab) market covered in this report is segmented –
1) By Indication: Plaque Psoriasis, Psoriatic Arthritis, Crohn’s Disease, Ulcerative Colitis, Other Indications
2) By Route Of Administration: Subcutaneous Injection, Intravenous Infusion
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
4) By End User: Pediatric, Adult, Geriatric
Which Trends Are Contributing To Changes In The Stelara (Ustekinumab) Market?
Leading companies within the stelara (ustekinumab) market are developing innovative products, including biosimilars to stelara, to offer a cost-effective treatment alternative for patients with chronic inflammatory conditions. Stelara biosimilars are biologically analogous medications created to replicate the therapeutic effects of Stelara (Ustekinumab), by targeting IL-12 and IL-23 to manage autoimmune diseases like psoriasis and psoriatic arthritis. For instance, in October 2024, Accord BioPharma Inc., a US-based biopharmaceutical company, reported the U.S. Food and Drug Administration (FDA) approval of IMULDOSA (ustekinumab-srlf), a biosimilar to Johnson & Johnson’s STELARA (ustekinumab). IMULDOSA is distinguished by its wide range of indications, providing treatment for adult patients with moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn’s disease, and ulcerative colitis. It also possesses a unique indication for pediatric patients aged 6 years and older with moderate to severe plaque psoriasis and active psoriatic arthritis, making it adaptable across different age groups. This extensive coverage establishes IMULDOSA as a valuable option for managing various immune-mediated inflammatory diseases.
Who Are The Active Companies Shaping The Stelara (Ustekinumab) Market?
Major companies operating in the stelara (ustekinumab) market are Johnson & Johnson
Get The Full Stelara (Ustekinumab) Market Report:
https://www.thebusinessresearchcompany.com/report/stelara-ustekinumab-global-market-report-
Which Region Represents The Largest Share Of The Stelara (Ustekinumab) Market?
North America was the largest region in the stelara (ustekinumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the stelara (ustekinumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Stelara (Ustekinumab) Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/stelara-ustekinumab-global-market-report-
Browse Through More Reports Similar to the Global Stelara (Ustekinumab) Market 2026, By The Business Research Company
Stevia Market Report 2026
https://www.thebusinessresearchcompany.com/report/stevia-global-market-report
Stearic Acid Market Report 2026
https://www.thebusinessresearchcompany.com/report/stearic-acid-global-market-report
Sarcoma Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/sarcoma-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model